» Articles » PMID: 39596891

Myo-Inositol and Its Derivatives: Their Roles in the Challenges of Infertility

Overview
Journal Biology (Basel)
Publisher MDPI
Specialty Biology
Date 2024 Nov 27
PMID 39596891
Authors
Affiliations
Soon will be listed here.
Abstract

Myo-inositol (MYO) and D-chiro-inositol (DCI) are the two most significant isomeric forms of inositol, playing a critical role in intracellular signaling. MYO is the most abundant form of inositol in nature; DCI is produced from MYO through epimerization by an insulin-dependent enzyme. Recently, it has been demonstrated that inositol may influence oocyte maturation and improve intracellular Ca oscillation in the oocytes, and it has been proposed as a potential intervention for restoring spontaneous ovulation. The MYO concentration in human follicular fluid is considered a bioindicator of oocyte quality. In the ovary, DCI modulates the activity of aromatase, thus regulating androgen synthesis. Under physiological conditions, the MYO/DCI ratio is maintained at 40:1 in plasma. In women with PCOS, the MYO/DCI ratio is lowered to 0:2:1, contributing to elevated androgen production. By regulating FSH signaling, MYO administration increases the number of high-quality embryos available for transfer in poor responder patients. Finally, by acting downstream to insulin signaling, inositol administration during pregnancy may represent a novel strategy for counteracting gestational diabetes. These findings show that diet supplementation with inositol may be a promising strategy to address female infertility and sustain a healthy pregnancy.

Citing Articles

The ameliorative effect of myo-inositol on apoptosis-related genes expression in cumulus cells of women with polycystic ovary syndrome undergoing ICSI and its relationship with the quality of oocyte and embryo.

Yazdanpanah Z, Heydari Nasrabadi M, Cheraghi E, Salehipour M Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40019528 DOI: 10.1007/s00210-025-03952-z.

References
1.
Bhide P, Pundir J, Gudi A, Shah A, Homburg R, Acharya G . The effect of myo-inositol/di-chiro-inositol on markers of ovarian reserve in women with PCOS undergoing IVF/ICSI: A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2019; 98(10):1235-1244. DOI: 10.1111/aogs.13625. View

2.
Byun S, JENNESS R . Estimation of free myo-inositol in milks of various species and its source in milk of rats (Rattus norvegicus). J Dairy Sci. 1982; 65(4):531-6. DOI: 10.3168/jds.S0022-0302(82)82230-3. View

3.
Sun T, Heimark D, Nguygen T, Nadler J, Larner J . Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun. 2002; 293(3):1092-8. DOI: 10.1016/S0006-291X(02)00313-3. View

4.
Akbari Sene A, Tabatabaie A, Nikniaz H, Alizadeh A, Sheibani K, Mortezapour Alisaraie M . The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial. Arch Gynecol Obstet. 2019; 299(6):1701-1707. DOI: 10.1007/s00404-019-05111-1. View

5.
Kucuk T, Kozinoglu H, Kaba A . Growth hormone co-treatment within a GnRH agonist long protocol in patients with poor ovarian response: a prospective, randomized, clinical trial. J Assist Reprod Genet. 2008; 25(4):123-7. PMC: 2582075. DOI: 10.1007/s10815-008-9212-7. View